Achillea millefolium for COVID-19

Achillea millefolium may be beneficial for COVID-19 according to the study below. COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 12,000+ potential treatments. c19early.org analyzes 220+ treatments. We have not reviewed Achillea millefolium in detail.

Protocol efficacy and cost by country

Treatment protocols varied widely

November 2026
Efficacy of protocol
SeychellesSCIcelandISBelizeBZMaltaMTLuxembourgLUMontenegroMEBhutanBTGuyanaGYComorosKMFijiFJDjiboutiDJCyprusCYMauritiusMUEstoniaEETrinidad and TobagoTTEquatorial GuineaGQBahrainBHLatviaLVGuinea-BissauGWSloveniaSINorth MacedoniaMKLesothoLSGabonGABotswanaBWGambiaGMNamibiaNALithuaniaLTAlbaniaALQatarQAJamaicaJMArmeniaAMMongoliaMNBosnia and HerzegovinaBAUruguayUYEritreaERGeorgiaGECroatiaHRPanamaPAMauritaniaMRNew ZealandNZCentral African RepublicCFIrelandIELiberiaLRCosta RicaCRNorwayNOSlovakiaSKCongoCGFinlandFIDenmarkDKSingaporeSGEl SalvadorSVKyrgyzstanKGNicaraguaNILebanonLBLibyaLYBulgariaBGParaguayPYHong KongHKSierra LeoneSLTogoTGSwitzerlandCHIsraelILSerbiaRSPapua New GuineaPGAustriaATBelarusBYTajikistanTJHungaryHUUnited Arab EmiratesAEHondurasHNSwedenSEAzerbaijanAZPortugalPTJordanJOGreeceGRCzechiaCZDominican RepublicDOSouth SudanSSCubaCUHaitiHTBelgiumBEBoliviaBOTunisiaTNBurundiBIBeninBJRwandaRWGuineaGNZimbabweZWChadTDCambodiaKHSenegalSNNetherlandsNLSyriaSYEcuadorECGuatemalaGTZambiaZMKazakhstanKZMalawiMWRomaniaROMaliMLBurkina FasoBFSri LankaLKTaiwanTWNigerNEAustraliaAUCôte d'IvoireCICameroonCMMadagascarMGVenezuelaVENepalNPYemenYEGhanaGHMozambiqueMZMalaysiaMYAngolaAOPeruPEUzbekistanUZSaudi ArabiaSAMoroccoMACanadaCAPolandPLAfghanistanAFIraqIQUkraineUASudanSDAlgeriaDZArgentinaARUgandaUGSpainESColombiaCOSouth KoreaKRKenyaKEMyanmarMMSouth AfricaZAItalyITFranceFRUKGBThailandTHGermanyDEIranIRTurkeyTRDR CongoCDVietnamVNEgyptEGPhilippinesPHEthiopiaETJapanJPMexicoMXRussiaRUBangladeshBDNigeriaNGBrazilBRPakistanPKIndonesiaIDUSAUSIndiaINChinaCNmore effective, cheaperless effective, costlier
0%20%40%60%
$0$500$1,000$1,500
Cost per course

Cost and estimated efficacy of national COVID-19 protocols; area is proportional to population. Countries are named where there is room, with more populous countries first and in darker type; hover any dot for details.

Cherneva et al., Traditional Use of Medicinal Plants for Symptom Relief During the COVID-19 Pandemic in Bulgaria, Plants, doi:10.3390/plants14233692
The COVID-19 pandemic has renewed global interest in medicinal plants as accessible sources of prophylactic and supportive therapies. Ethnobotanical research provides an important foundation for developing plant-based medicines with preventive and therapeutic potential. This study aimed (1) to investigate the distribution and indications for the use of medicinal plants in the prevention and relief of COVID-19-related symptoms among the Bulgarian population, and (2) to identify culturally significant species with potential for further development as antiviral agents. A total of 513 respondents from different regions and demographic groups in Bulgaria were interviewed. Their knowledge regarding the use of medicinal plants for COVID-19 prevention or treatment was quantitatively assessed using ethnobotanical indices: relative frequency of citation (RFC), informant consensus factor (FIC), fidelity level (FL), and use value (UV). Participants reported 45 species belonging to 43 genera and 23 families. The highest RFC and UVs were recorded for Matricaria chamomilla L., Tilia sp., Thymus vulgaris L., Zingiber officinale Roscoe, Mentha sp., Citrus x limon (L.) Osbeck, Rosa canina L., and Sideritis scardica Griseb. Culturally significant species identified were Thymus vulgaris L., Matricaria chamomilla L., Tilia sp., Mentha sp., Sideritis scardica Griseb, Zingiber officinale Roscoe, and Citrus x limon (L.) Osbeck. This ethnobotanical survey in Bulgaria documents culturally important medicinal plants that may have potential applications in prophylaxis and complementary therapy for COVID-19.